MedX Health Corp. Appoints Sylvain Desjeans as CEO

MedX Health Corporation, a global leader in teledermatology, has appointed Sylvain Desjeans as president and CEO.
 
With more than 30 years of healthcare and pharmaceutical industry experience, Desjeans served in successively senior roles at organizations such as Aspen Pharmacare Canada, Accucaps Industries Limited, and Biovail Pharmaceuticals. He has a long track record of successfully executing large-scale growth plans and global product licensing initiatives.

“Sylvain brings extensive knowledge of, and experience in, the global medical technology market,” said Rob von der Porten, chairman of the MedX Board of Directors. “As a leader, he is exceptional at building sales, opening distribution channels and developing high-performing teams that deliver results, all of which are imperative for MedX to achieve our growth plans in Canada, the U.S. and internationally.”
 
Desjeans joined MedX as chief revenue officer, and has been working on the company’s market opportunities, including the application of the MedX Dermsecure platform’s artificial intelligence features, as well as initiatives focussed on revenue generation. His appointment follows a comprehensive recruitment process led by the MedX Board of Directors.
 
Desjeans stated, “I am honoured at this appointment, and I look forward to helping MedX realize its potential during a time of substantial growth for the company. We’ve learned from the challenges of the COVID-19 pandemic that there is a strong need for increasing access and speed to healthcare for patients. I’m energized by the fact that our products are uniquely positioned to maintain a leadership position in this industry. Ultimately, our purpose at MedX is to save lives.”
 
MedX’s telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image-capture technology, SIAscopy, and its secure, cloud-based patient management system, DermSecure, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
 
Teledermatology, is a subspecialty of dermatology that offers safe and effective virtual patient assessment and diagnosis at a distance, eliminating the need for in-person appointments. As the world continues to navigate through ongoing COVID-19 recovery measures, teledermatology’s advancement has never been more critical to patient care and outcomes.
 
MedX, headquartered in Mississauga, Ontario, is a medical device and software company focused on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is also imbedded in its products SIAMETRICS, SIMSYS, and MoleMate, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS, SIMSYS, and MoleMate include handheld devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil, and Turkey.